fda warns against compounded semaglutide issued 25 warning letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA warns against using compounded

What makes GLP-1 different from other weight loss treatments available

This represents a precautionary approach rather than a requirement based on proven deficiency risk

Recent FDA Guidance on Compounded GLP-1s: In October 2023, the FDA issued warnings about compounded GLP-1 medications, specifically cautioning patients to ensure theyre receiving semaglutide (the actual FDA-approved ingredient) rather than semaglutide salts, which have different properties

HOW TO GET STARTED: Create your account on Ro.co first, then log into the app

However, larger clinical trials are still needed to confirm these positive results